Pellegatta, S., Eoli, M., Cuccarini, V., Anghileri, E., Pollo, B., Pessina, S., . . . Finocchiaro, G. (2018). Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8(+) T cell activation in the presence of adjuvant temozolomide. Oncoimmunology.
Citação norma ChicagoPellegatta, Serena, et al. "Survival Gain in Glioblastoma Patients Treated With Dendritic Cell Immunotherapy Is Associated With Increased NK but Not CD8(+) T Cell Activation in the Presence of Adjuvant Temozolomide." Oncoimmunology 2018.
Citação norma MLAPellegatta, Serena, et al. "Survival Gain in Glioblastoma Patients Treated With Dendritic Cell Immunotherapy Is Associated With Increased NK but Not CD8(+) T Cell Activation in the Presence of Adjuvant Temozolomide." Oncoimmunology 2018.